# STOP-T1D Low-Dose (ATG)

> **NCT04291703** · PHASE2 · TERMINATED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 2 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Antithymocyte Globulin
- **DRUG:** Placebo (for ATG)

## Key facts

- **NCT ID:** NCT04291703
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-01
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated early due to low enrollment and lack of feasibility to meet target enrollment.
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04291703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04291703, "STOP-T1D Low-Dose (ATG)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT04291703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*